Editas Medicine, Inc. (EDIT)
Chart Events
Performance Outlook
| Previous Close | 60.68 |
| Open | 58.88 |
| Bid | 60.71 x 1000 |
| Ask | 61.00 x 1800 |
| Day's Range | 54.04 - 62.50 |
| 52 Week Range | 14.01 - 99.95 |
| Volume | 2,926,022 |
| Avg. Volume | 2,485,001 |
| Market Cap | 3.873B |
| Beta (5Y Monthly) | 2.10 |
| PE Ratio (TTM) | N/A |
| EPS (TTM) | -1.63 |
| Earnings Date | Feb 25, 2021 - Mar 02, 2021 |
| Forward Dividend & Yield | N/A (N/A) |
| Ex-Dividend Date | N/A |
| 1y Target Est | 44.38 |
- Motley Fool
Is Editas Medicine a Buy?
Editas Medicine (NASDAQ: EDIT) is quickly becoming one of the hottest biotech and gene therapy stocks on the market. Meanwhile, the industry indicator, iShares NASDAQ Biotechnology Index (NASDAQ: IBB), only returned a total of 41%. The most mind-boggling aspect of Editas is that the company already has a staggering $4.1 billion market cap -- despite having no therapies out on the market.
- Zacks
Editas Medicine (EDIT) Stock Sinks As Market Gains: What You Should Know
In the latest trading session, Editas Medicine (EDIT) closed at $65.47, marking a -0.44% move from the previous day.
- Motley Fool
Why I'm Betting Big on This 1 Megatrend
Wayne Gretzky hung up his hockey sticks a long time ago. Although Gretzky's quote has become something of a cliche, it nonetheless remains highly relevant in many areas -- including investing. For investors, the idea is the same concept that Gretzky articulated years ago: Focus on what's going to happen in the future.
